After adjusting for pretherapy variables, the multivariable analysis demonstrated a lower risk for time to first severe infections with CAR-T compared to BsAb, but this did not reach statistical significance (HR 0.60, 95% CI 0.31−1.17, P = 0.14) – Table 2 .
← all excerpts
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
1
0.1400
0.1400